StemCell Therapy

Despite the ethical questions, the field of stem cell research has not slowed particularly within the field of regenerative medicine where the potential for cellular regeneration to kickstart the body's repair mechanism is huge.

But is it as simple as gathering stem cells, putting them into the human body and seeing how things go?

First lets understand the balance within our bodies. Take for example bones, made up by the balance of two types of cell, osteoblasts (builders) and oesteoclasts (dissolvers).

If the body has excess osteoblasts it can lead to abnormal bone growth such as bunions through to Pagets disease. And too many osteoclast cells can lead to bone degeneration conditions such as osteoporosis. Stem cells as the natural building blocks of the body could be used to tell the existing cells how they should be acting to get the balance back and avoid these issues.

While in principle this sounds good, when it comes to degenerative diseases such as Parkinsons, multiple sclerosis, neurodegeneration and cancer, these are complex conditions where imbalances in cell development and chronic inflammation need a more detailed and complete "message" to resolve these issues.

In short, and in keeping with the theme of the US election, rather than rely on multiple random and chaotic tweets from the President, what is required is a more detailed email explaining what each cell should be doing to ensure a harmonious operating environment.

In the 1990s researchers identified that exosomes that secrete naturally from cells were not nanoparcel debris as first thought. Rather, exosomes are bioactive and have the specialised function of carrying messages to other cells in the body instructing them on how they should act.

So if exosomes could be harvested and then delivered to the specific area of the body that needs them, they could aid the bodys healing process.

Excitingly there is a listed Australian company at the forefront of this field of work. Exopharm is the owner of proprietary manufacturing technology called LEAP, which performs the exosome extraction and purification process.

The technology created by the company's chief executive, Ian Dixon, is designed to complete the purification process and facilitate the mass production of pharmaceutical-grade exosomes.

The company has candidates in testing and development, ranging from wound healing to curing dry age-related macular degeneration. Further, it recently signed exclusive IP agreements for the delivery of engineered extracellular vesicles (EEV) which can be designed to carry specific cargos to target particular cells or tissue to cure illnesses.

From an investment perspective, the exciting thing that Exopharm offers is the potential for numerous products to be commercialised using its manufacturing process. It will seek licensing arrangements and partnerships with other parties to deliver their drugs at scale using Exopharm technology

Dixon is supported by a team with experience from big pharma, including Alison Mew, previously a senior manager at CSL and now director of manufacturing and development at Exopharm.

While all biotech firms at the pre-revenue stages carry risks, specifically regulatory and financial, in the case of the latter this is somewhat mitigated for Exopharm as it seeks a model where there are upfront licensing payments for the early stage work with the potential for milestone payments and royalties in the longer term.

While this field of study may seem like science fiction, it is actively pursued in laboratories and discussed in medical journals all over the world, with large pharma refocusing their stem cell work to accommodate the development of exosomes.

Underpinned by the size of the global regenerative medicine market estimated at $US100 billlion ($141 billion) per annum and growing, the prospects for this innovative world leader look positive.

Disclaimer: Spotee and/or its directors, employees, representatives and associates hold an interest in Exopharm.

See more here:
Ways to cash in on regenerative medicine - The Australian Financial Review

This entry was posted on October 28, 2020 at 10:54 am and is filed under Regenerative Medicine. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |